

CureMetrix Announces Showcase at 2023 Society of Breast Imaging (SBI) Symposium

CureMetrix® will demonstrate technology that leverages artificial intelligence (AI) to accelerate the early detection of breast cancer and heart disease at SBI.

SAN DIEGO, CA, UNITED STATES, April 25, 2023 /EINPresswire.com/ --

[CureMetrix®](#), Inc, a leading provider of AI-powered medical imaging solutions, is pleased to announce its participation at the 2023 Society of Breast Imaging (SBI) Breast Imaging Symposium,

taking place from May 4-7 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.



The SBI Symposium provides an opportunity for breast imaging specialists and healthcare

“

We look forward to showcasing our cutting-edge technology and collaborating with other leaders in the field to advance the detection of both breast cancer and heart disease.”

*Kevin Harris, President of
CureMetrix*

professionals to network and learn about the latest advancements in breast imaging technology. This year's event will feature a range of sessions, including lectures, case reviews, and interactive workshops. CureMetrix representatives will be in attendance at SBI, and will offer demonstrations of its flagship products for advanced breast cancer and heart disease detection at booth #431.

CureMetrix will showcase the following AI-powered [mammography solutions](#) at SBI:

□ cmTriage® – The first FDA-cleared software for breast imaging triage, which provides a notification triage code to

a radiologist’s mammography worklist allowing them to sort and prioritize scans based on the presence of suspicious marks.

□ cmAssist® – An investigational computer-aided detection (CAD) software that leverages AI to help radiologists identify, mark, and score regions of interest on screening mammograms.

□ cmDensity™ – An AI-based detection software that helps radiologists accurately and consistently classify breast density, a critical factor in correctly diagnosing breast cancers.

□ cmAngio® – A groundbreaking investigational AI-based detection software that helps doctors assess a patient's age-adjusted risk of heart disease.

"CureMetrix is proud to be a part of the SBI Breast Imaging Symposium," said Kevin Harris, President of CureMetrix. "We are ready to engage with industry experts and healthcare professionals as trusted partners in the field of breast imaging at this exciting event. We look forward to showcasing our cutting-edge technology and collaborating with other leaders in the field to advance the detection of both breast cancer and heart disease."

View the full SBI Symposium agenda and exhibitor list [here](#).

To learn more about AI-powered breast imaging solutions by CureMetrix, please visit: www.curemetrix.com.

About CureMetrix

CureMetrix is a global leader in Artificial Intelligence for medical imaging, committed to advancing technology that improves disease detection and cancer survival rates across the globe. Its mission is to help save lives with early and more accurate disease detection and support improved clinical and financial outcomes, delivering technology that radiologists, healthcare systems, and patients can rely on with confidence. Visit www.CureMetrix.com

Disclaimer: cmTriage® is FDA-cleared for commercial use in the U.S. cmTriage® and cmAssist® are ANVISA cleared in Brazil. cmAngio® and cmDensity™ are in development and not available for commercial use in any country.

Brock Anderson
CureMetrix
brock@curemetrix.com
Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/629319730>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.